AMICUS THERAPEUTICS INC (FOLD)
Sector: Health Care
2025 Annual Meeting Analysis
AMICUS THERAPEUTICS INC · Meeting: June 5, 2025
Directors FOR
4
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Four Class III Directors
Kelly joined in December 2020 (under 24 months exempt threshold does not apply as he has served ~4.5 years), but FOLD's 3-year return of +32.4% is strong positive and the gap versus the compensation peer group median (-15.6pp) falls well below the 65pp trigger threshold; no overboarding (3 public boards), attendance 94%, and he brings relevant life sciences finance expertise.
McGlynn has served since 2009; the 3-year TSR gap versus the peer group (-15.6pp) is well below the 65pp trigger threshold for strong-positive absolute TSR; she chairs Novavax (NVAX) and previously served on other boards but currently holds 2 public board seats (FOLD + NVAX), so no overboarding concern; attendance 100% and she brings deep pharma commercialization experience.
Raab has served since 2004 and is a sitting CEO of Ardelyx (ARDX) as well as Chairman of FOLD and Chairman of Tempest Therapeutics — that is 3 public board seats as a sitting CEO, which exceeds the policy limit of 2 outside public board seats for sitting CEOs; however the 3-year TSR trigger does not fire (gap -15.6pp vs. 65pp threshold), attendance is 100%, and his role is Chair of the Board with no independence concern — flagging the overboarding issue.
Sblendorio has served since 2006; the 3-year TSR gap (-15.6pp) is well below the 65pp trigger threshold; he chairs Mineralys Therapeutics and serves on Nanoscope (private), so public board count is 2 (FOLD + MLYS), no overboarding; attendance 100% and he is the designated audit committee financial expert with extensive CFO/CEO experience in biopharma.
All four Class III director nominees pass the primary TSR trigger — FOLD's 3-year absolute return of +32.4% (strong positive tier) requires a 65pp gap versus the compensation peer group median to fire a No vote, and the actual gap is only -15.6pp. A technical overboarding flag exists for Michael Raab (sitting CEO of Ardelyx who also chairs FOLD and chairs Tempest Therapeutics, totaling 3 public board seats as a CEO), but given his central governance role as independent Chairman, 100% attendance, and the absence of any TSR or qualification concern, a FOR vote is supported across the full slate.
Say on Pay
✓ FORCEO
Bradley L. Campbell
Total Comp
$8,526,943
Prior Support
97%%
CEO total compensation of $8.53 million is reasonable for a biotech CEO at a $4.5B company and is consistent with the company's self-reported targeting of the 50th percentile of its peer group; pay mix is strongly variable — approximately 84% of the CEO's pay is in long-term equity (stock options, time-based stock awards, and performance stock awards), well above the 50-60% minimum threshold, and the company's fixed salary is only about 9% of total pay. The performance stock awards use meaningful, disclosed metrics including relative total shareholder return versus the Nasdaq Biotechnology Index, revenue goals, and pipeline goals, and the 2022 performance stock awards paid out at 88.6% of target reflecting genuine performance discipline; the prior year say-on-pay vote received 97% support, no concerns are triggered, and the company maintains a robust clawback policy aligned with Nasdaq/Dodd-Frank requirements.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
$2,555,948
Non-Audit Fees
$48,783
Non-audit fees (tax fees of $20,600 plus all other fees of $28,183 = $48,783) represent approximately 1.9% of audit fees ($2,555,948), well below the 50% threshold that would trigger a No vote; EY is a Big 4 firm appropriate for a $4.5B market cap company; auditor tenure is not disclosed in the proxy so the tenure trigger cannot fire per policy; no material restatements are noted.
Overall Assessment
The 2025 Amicus Therapeutics annual meeting presents a clean ballot with no material governance concerns: all four director nominees pass the TSR trigger by a wide margin, Ernst & Young's fee structure raises no independence issues, and the compensation program is well-structured with strong performance linkage and a 97% prior-year say-on-pay approval rate. The only item outside policy coverage is the 2025 Equity Incentive Plan, which is noted but not evaluated under the current policy version.
Compensation Peer Group
17 companies disclosed in 2025 proxy filing